Currently out of the existing stock ratings of Jeffrey Hung, 85 are a HOLD (39.35%), 14 are a SELL (6.48%), 117 are a BUY (54.17%).

Jeffrey Hung

Work Performance Price Targets & Ratings Chart

Analyst Jeffrey Hung, currently employed at MORGAN STANLEY, carries an average stock price target met ratio of 56.72% that have a potential upside of 26.21% achieved within 158 days.

Jeffrey Hung’s has documented 420 price targets and ratings displayed on 31 stocks. The coverage is on the Healthcare sector.

Most recent stock forecast was given on ACAD, ACADIA Pharmaceuticals at 07-Mar-2025.

Wall Street Analyst Jeffrey Hung

Analyst best performing recommendations are on INSM (INSMED).
The best stock recommendation documented was for RYTM (RHYTHM PHARMACEUTICALS) at 11/9/2022. The price target of $26 was fulfilled within 2 days with a profit of $3.75 (16.85%) receiving and performance score of 84.27.

Average potential price target upside

of $85.66 (44.39%) on KRTX (KARUNA THERAPEUTICS).
of $28.8 (16.58%) on APRE (APREA THERAPEUTICS).
of $19.73 (18.67%) on NBIX (NEUROCRINE BIOSCIENCES).

ACAD ACADIA Pharmaceuticals CYTK Cytokinetics ESPR Esperion Therapeutics EVFM Evofem Biosciences EXEL Exelixis PRLD Prelude Therapeutics RARE Ultragenyx VYGR Voyager Therapeutics APRE Aprea Therapeutics BCYC Bicycle Therapeutics Ltd JAZZ Jazz Pharmaceuticals PLC MYOK MyoKardia NBIX Neurocrine Biosciences NXTC NextCure RPTX Repare Therapeutics CELU Celularity CGEM Cullinan Oncology LLC CINC CinCor Pharma GRPH Graphite Bio RUBY Rubius Therapeutics CYT Cyteir Therapeutics RYTM Rhythm Pharmaceuticals XLRN Acceleron Pharma ERAS Erasca IMRX Immuneering Corp ITCI Intracellular Th KRTX Karuna Therapeutics PTCT PTC Therapeutics CRNX Crinetics Pharmaceuticals FOLD Amicus Therapeutics INSM Insmed

Show more stocks

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Jeffrey Hung (MORGAN STANLEY)